SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification

被引：3
|
作者：
Yu, Y. [1 ]
Yang, N. [2 ]
Zhang, Y. [3 ]
Zhang, H. [4 ]
Li, M. [5 ,16 ]
Yu, Q. [6 ]
Zhou, J. [7 ]
Hu, X. [8 ]
Fang, J. [9 ]
Zhao, H. [10 ]
Feng, J. [11 ]
Li, L. [12 ]
Shu, Y. [13 ]
Wang, X. [14 ]
Sun, M. [15 ]
Zhang, J. [15 ]
Li, M. [5 ,16 ]
Ren, Y. [15 ]
Lu, S. [1 ]
机构：
[1] Shanghai Chest Hosp, Dept Oncol, Shanghai, Peoples R China
[2] Hunan Canc Hosp, Pulm Gastroenterol, Changsha, Peoples R China
[3] Zhejiang Canc Hosp, Med Oncol, Hangzhou, Peoples R China
[4] Guangdong Prov Hosp Chinese Med, Dept Internal Med 1, Guangzhou, Peoples R China
[5] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China
[6] Guangxi Med Univ, Affiliated Tumor Hosp, Resp Oncol Dept, Nanning, Peoples R China
[7] Zhejiang Univ, Affiliated Hosp 1, Resp Med Dept, Hangzhou, Peoples R China
[8] Henan Tumor Hosp, Med Oncol, Zhengzhou, Peoples R China
[9] Beijing Canc Hosp, Dept Thorac Oncol, Beijing, Peoples R China
[10] Anhui Med Univ, Hosp 2, Dept Pneumol, Hefei, Peoples R China
[11] Nantong Univ, Affiliated Hosp, Dept Resp & Crit Care Med, Nantong, Peoples R China
[12] Sichuan Univ, West China Hosp, Resp Dept, Lung Canc Ctr, Chengdu, Peoples R China
[13] Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China
[14] Shandong Univ, Qilu Hosp, Dept Chemotherapy, Jinan, Peoples R China
[15] Haihe Biopharma Co Ltd, CSSD, Shanghai, Peoples R China
[16] Haihe Biopharma Co Ltd, BDS, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
305MO
引用
下载
收藏
页码：S1553 / S1553
页数：1
相关论文
共 50 条
  • [1] Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
    Liam, C. K.
    Ahmad, A. Rozila
    Hsia, T.
    Li, J. Y.
    Le, X.
    Heymach, J.
    Yang, J. C.
    Soo, R.
    Zhang, Y.
    Kim, S.
    Shin, S. W.
    Johne, A.
    Karachaliou, N.
    Bruns, R.
    Ellers-Lenz, B.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1118 - S1119
  • [2] Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification
    Wu, Yi-Long
    Han, Ji-Youn
    Kato, Terufumi
    Barlesi, Fabrice
    Garon, Edward B.
    Cappuzzo, Federico
    Shibata, Yuji
    Smith, Nathalie
    Khanna, Sadhvi
    Belli, Riccardo
    Yovine, Alejandro
    Tan, Daniel
    CANCER RESEARCH, 2022, 82 (12)
  • [3] Capmatinib plus osimertinib versus platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIb/IIIc or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification.
    Wu, Yi-Long
    Han, Ji-Youn
    Kato, Terufumi
    Barlesi, Fabrice
    Garon, Edward B.
    Cappuzzo, Federico
    Shibata, Yuji
    Smith, Nathalie
    Khanna, Sadhvi
    Belli, Riccardo
    Yovine, Alejandro Javier
    Tan, Daniel S. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
    Remon, J.
    Steuer, C. E.
    Ramalingam, S. S.
    Felip, E.
    ANNALS OF ONCOLOGY, 2018, 29 : I20 - I27
  • [5] Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
    Liam, C. K.
    Kim, T. M.
    Yang, J-J.
    Huang, C.
    Voon, P-J.
    Tho, L. M.
    Zhou, Q.
    Wang, J.
    Hayashi, H.
    Tan, D. S. W.
    Danchaivijitr, P.
    Nguyen, V. N.
    Wong, K. H.
    Yang, J. C-H.
    Le, X.
    Ellers-Lenz, B.
    Karachaliou, N.
    Ghori, V.
    Berghoff, K.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1691 - S1691
  • [6] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul, S.
    Mun, T. L.
    Wang, C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
  • [7] The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients
    Huang, Y. H.
    Hsu, K. -H.
    Tseng, J. -S.
    Chen, K. -C.
    Chang, G. -C.
    Yang, T. -Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S477 - S478
  • [8] Tepotinib plus gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT
    Liam, Chong Kin
    Ahmad, Azura Rozila
    Hsia, Te-Chun
    Zhou, Jianying
    Kim, Dong-Wan
    Soo, Ross Andrew
    Cheng, Ying
    Lu, Shun
    Shin, Sang Won
    Yang, James Chih-Hsin
    Zhang, Yiping
    Zhao, Jun
    Bruns, Rolf
    Johne, Andreas
    Wu, Yi-Long
    CANCER RESEARCH, 2022, 82 (12)
  • [9] Tepotinib plus gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT
    Itchins, Malinda
    Liam, Chong Kin
    Ahmad, Azura
    Hsia, Te-Chun
    Zhou, Janying
    Kim, Dong-Wan
    Soo, Ross Andrew
    Cheng, Ying
    Lu, Shun
    Shin, Sang Won
    Yang, James Chih-Hsin
    Zhang, Yiping
    Zhao, Jun
    Bruns, Rolf
    Johne, Andreas
    Wu, Yi-Long
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 82 - 83
  • [10] INSIGHT 2: Tepotinib plus Osimertinib in EGFR-Mutant NSCLC with Resistance to 1st-Line Osimertinib due to MET Amplification
    Smit, E.
    Felip, E.
    Karachaliou, N.
    Ellers-Lenz, B.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S36 - S36
12345